Allos Therapeutics to Report Third Quarter 2009 Results on November 3, 2009

Allos Therapeutics, Inc. (NASDAQ:ALTH), a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics, today announced that Company management will provide a corporate update and review of the third quarter 2009 results via webcast and conference call on Tuesday, November 3, 2009, at 4:30 p.m. ET.

To access the live audio webcast or the subsequent archived recording, visit the “Investors - Presentations and Events” section of the Company’s website at www.allos.com. Alternatively, callers may participate in the conference call by dialing 1-877-941-8610 (domestic) or 480-629-9819 (international). Participants should reference the Allos Therapeutics conference call. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through Friday, November 13, 2009. To access the replay, callers should dial 1-800-406-7325 (domestic) or 303-590-3030 (international) and use passcode 4169927#.

About Allos Therapeutics

Allos Therapeutics, Inc. (Nasdaq:ALTH) is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. Allos is currently focused on the development and commercialization of FOLOTYNTM (pralatrexate injection), a folate analogue metabolic inhibitor. FOLOTYN is the first and only drug approved in the U.S. for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Allos is also developing FOLOTYN in other potential indications. Allos retains exclusive worldwide rights to FOLOTYN for all indications. Allos is headquartered in Westminster, CO. For additional information, please visit www.allos.com.

Safe Harbor Statement

The 2009 third quarter results press release and conference call will contain forward-looking statements that involve significant risks and uncertainties, including those contained in the "Risk Factors" section of the company's Form 10-Q for the quarter ended June 30, 2009 and in the company's other periodic reports and filings with the Securities and Exchange Commission. Allos is providing the information contained in the press release and conference call as of the date of the release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise. The Company cautions investors not to place undue reliance on the forward-looking statements contained in the press release or the conference call. No forward-looking statement can be guaranteed and actual events and results may differ materially from those projected.